Aduro Biotech, a immuno-oncology company based in Berkeley, California announced that the FDA has granted Orphan Drug Designation for its CRS-207, an immuno-oncology product in development for the treatment of mesothelioma.  The FDA previously granted Orphan Drug Designation to CRS-207 and GVAX Pancreas together for the treatment of pancreatic cancer.  Mesothelioma is a rare form of cancer originated from mesothelial cells lining many of the internal organs, such as the chest, lungs, heart and abdomen.  CRS-207 is a drug candidate developed from on Aduro’s live-attenuated, double-deleted (LADD) Listeria monocytogenes immunotherapy platform.

Related Links:

http://www.aduro.com/view.cfm/121/press-release